Enanta Pharmaceuticals, Inc. (ENTA) vs Orchestra BioMed Holdings, Inc. (OBIO)

Enanta Pharmaceuticals, Inc. and Orchestra BioMed Holdings, Inc. are both Biotechnology companies. Enanta Pharmaceuticals, Inc. and Orchestra BioMed Holdings, Inc. are of similar size ($366.0M and $349.5M). Orchestra BioMed Holdings, Inc. grew revenue faster over the last twelve months: 986.1% against 0.70%. Enanta Pharmaceuticals, Inc. has the higher net margin (−96.9% vs −186.3%) and the higher return on invested capital (0.00% vs 0.00%). Across the 16 metrics below, Enanta Pharmaceuticals, Inc. leads on 11 and Orchestra BioMed Holdings, Inc. on 5.

Valuation

Metric ENTA OBIO Biotechnology median
P/E n/m n/m 7.88
P/S 5.30 11.87 11.47
P/B 3.42 19.65 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 2.39 9.52 10.73
Earnings yield (20.29%) (14.29%) (28.84%)
Free cash flow yield (10.69%) (15.57%) (23.03%)

Profitability

Metric ENTA OBIO Biotechnology median
Gross margin 100.00% 99.51% 65.16%
Operating margin (89.99%) (181.36%) 0.00%
Net margin (96.89%) (186.30%) 0.00%
Free cash flow margin (56.60%) (184.83%) 0.00%
Return on equity (70.12%) (607.32%) (57.72%)
Return on assets (21.15%) (75.16%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ENTA OBIO Biotechnology median
Revenue growth (TTM) 0.70% 986.14% 5.64%
EPS growth (last fiscal year) 29.93% 33.13% —
Revenue growth, 5-year CAGR (11.81%) — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ENTA OBIO Biotechnology median
Debt to equity 0.00 1.80 0.00
Current ratio 3.76 8.26 4.73
Net debt to EBITDA 2.35 1.80 0.96

Dividend

Metric ENTA OBIO Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric ENTA OBIO Biotechnology median
Market cap 349.50m 366.04m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack